pharma · Advanced or metastatic solid tumors · Waldenström's Macroglobulinemia
BeiGene
BeiGene is a pharma organization headquartered in Camana Bay, KY. Primary therapeutic focus areas include Advanced or metastatic solid tumors, Waldenström's Macroglobulinemia, Covid19, Ovarian Cancer, Carcinoma, Hepatoce
55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US HQ
2010 Founded
2,047 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US
- Founded
- 2010
- Employees
- 2,047
- Programs
- 14
- Drugs
- 19
- Patents
- 25
Tislelizumab
Phase 3 · small molecule · Recurrent or Metastatic Nasopharyngeal Cancer
Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer is a Phase 3 program (small_molecule) at BeiGene with 1 ClinicalTrials.gov record(s).
Internal code BGB-A317-309
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- BeiGene
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Recurrent or Metastatic Nasopharyngeal Cancer
- Status
- completed
- Trials
- 1